Cost Of Revenue - Corcept Therapeutics Inc (NASDAQ:CORT) - Alpha Spread

Corcept Therapeutics Inc
NASDAQ:CORT

Watchlist Manager
Corcept Therapeutics Inc Logo
Corcept Therapeutics Inc
NASDAQ:CORT
Watchlist
Price: 43.93 USD 1.5% Market Closed
Market Cap: 4.8B USD
Have any thoughts about
Corcept Therapeutics Inc?
Write Note

Corcept Therapeutics Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Corcept Therapeutics Inc
Cost of Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Corcept Therapeutics Inc
NASDAQ:CORT
Cost of Revenue
-$8.5m
CAGR 3-Years
-18%
CAGR 5-Years
-9%
CAGR 10-Years
-33%
Johnson & Johnson
NYSE:JNJ
Cost of Revenue
-$26.5B
CAGR 3-Years
3%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Cost of Revenue
-$11.1B
CAGR 3-Years
-4%
CAGR 5-Years
-10%
CAGR 10-Years
-10%
Pfizer Inc
NYSE:PFE
Cost of Revenue
-$16B
CAGR 3-Years
-13%
CAGR 5-Years
N/A
CAGR 10-Years
-5%
Merck & Co Inc
NYSE:MRK
Cost of Revenue
-$15.1B
CAGR 3-Years
-3%
CAGR 5-Years
-3%
CAGR 10-Years
1%
Eli Lilly and Co
NYSE:LLY
Cost of Revenue
-$7.5B
CAGR 3-Years
-3%
CAGR 5-Years
-11%
CAGR 10-Years
-4%

See Also

What is Corcept Therapeutics Inc's Cost of Revenue?
Cost of Revenue
-8.5m USD

Based on the financial report for Jun 30, 2024, Corcept Therapeutics Inc's Cost of Revenue amounts to -8.5m USD.

What is Corcept Therapeutics Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-33%

Over the last year, the Cost of Revenue growth was -47%. The average annual Cost of Revenue growth rates for Corcept Therapeutics Inc have been -18% over the past three years , -9% over the past five years , and -33% over the past ten years .

Back to Top